Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaboNivo With or Without Ipilimumab in Advanced Genitourinary Tumors
NCT02496208Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2015
- Primary completion
- Jul 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of cabozantinib, nivolumab and ipilimumab in genitourinary cancer (2 arms), sponsored by National Cancer Institute. Primary endpoints: Recommended phase II dose and Incidence of adverse events. Started Jul 2015; status: active, not recruiting.
02
Drugs
03
Conditions
genitourinary cancer
Beyond the preview
Go deeper on NCT02496208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496208.